“冠军”涨超85%，上半年基金业绩排行揭晓

Core Viewpoint - The year 2025 presents both significant opportunities and challenges for fund investments, with various themes such as AI, robotics, semiconductors, and pharmaceuticals leading the market [2][3]. Fund Performance - As of June 30, 2025, the top five performing funds include: - Huatai-PineBridge Hong Kong Advantage Selection Fund with a return of 85.64% - CITIC Construction Investment North Exchange Selection Fund with a return of 82.45% - Great Wall Pharmaceutical Industry Selection Fund with a return of 75.18% - Huaxia North Exchange Innovation Small and Medium Enterprises Selection Fund with a return of 72.16% - Bank of China Hong Kong Stock Connect Pharmaceutical Fund with a return of 70.08% [2][7][16]. - The next five funds, with returns exceeding 61%, include: - Yongying Pharmaceutical Innovation Selection Fund - GF Growth Navigation Fund - Huaan Pharmaceutical Biotechnology Fund - Ping An Core Advantage Fund - Nuon Selected Value Fund [2][7]. Fund Manager Insights - Notable fund managers include: - Zhang Wei of Huatai-PineBridge, with a background in biomedical studies and extensive experience in the pharmaceutical sector [6]. - Leng Wenpeng of CITIC Construction Investment, who has a diverse career path in various investment firms [6]. - Liang Furui of Great Wall Fund, recognized for his rapid success in the pharmaceutical sector [6]. Mixed Fund Performance - The leading mixed fund is CITIC Construction Investment North Exchange Selection Fund, which focuses on North Exchange stocks, achieving a return of 82.45% [12][16]. - Other notable mixed funds include: - Great Wall Pharmaceutical Industry Selection Fund - Yongying Pharmaceutical Innovation Selection Fund - GF Growth Navigation Fund - Ping An Core Advantage Fund [13][16]. Index Fund Trends - In the index fund category, new entrants like Huatai-PineBridge, Yinhua, and Wanji have shown strong performance, with returns exceeding 57% [17][18]. QDII Fund Highlights - The top QDII fund is Huatai-PineBridge Hong Kong Advantage Selection Fund, with a return of 85.64%, primarily investing in Hong Kong stocks [19][22]. - Other strong performers include: - GF Hong Kong Innovation Pharmaceutical ETF - Huatai-PineBridge Hang Seng Innovation Pharmaceutical ETF, both with returns over 55% [20][22]. Bond Fund Performance - In the bond fund category, the top performer is Huashang Fengli Enhanced Open Fund with a return of 13.83% [24]. - Other notable bond funds include: - China Europe Convertible Bond Fund - Bosera Convertible Bond Enhanced Fund - Fuguo Optimized Enhanced Fund [24].